Signatope

Executive Summary

Signatope is a German biotechnology company specializing in next-generation quantitative immunoassays using antibodies that target ultra-short, 4-amino-acid epitopes. This unique technology enables precise quantification of proteins across different species, overcoming challenges associated with highly conserved or difficult targets such as drug transporters. Founded in 2017 and based in Munich, Signatope focuses on providing tailored assay services for drug safety and toxicology applications, particularly in kidney and liver injury, as well as CYP450 enzyme and transporter induction studies. By enabling cross-species protein quantification, the company addresses a critical need in preclinical drug development, where accurate biomarker measurement is essential for predicting human responses. While still in a private, early-stage phase with limited public information on funding or revenue, Signatope's innovative platform has the potential to become a standard tool in pharmaceutical toxicology and diagnostics. The company's emphasis on challenging protein targets positions it favorably in the growing precision medicine and companion diagnostics markets, though commercialization and scalability remain key challenges.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical partnership for drug safety assay development60% success
• Q4 2026Launch of first commercial quantitative assay kit50% success
• Q2 2026Series A funding round55% success